AVP Reinforces Its Leadership Team: Warda Shaheen Joins AVP as a General Partner for the AVP Late Stage Fund in Europe, while Pedro Barros Takes on the Role of Partner in Charge of Investor Relations
In the context of the launch of its Late Stage Fund, AVP continues to strengthen its leadership team to reinforce its global platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502656787/en/
(Photo: Business Wire)
First, after the recruitment of Elizabeth de Saint-Aignan in the USA, Warda's appointment in Europe completes the senior team of the new AVP Late Stage Fund.
Prior to joining AVP, Warda Shaheen held the position of Director at OMERS Growth Equity, where she conducted investments in prominent software companies such as Coveo, TouchBistro, PandaDoc, Clio, Celigo and GitLab. Previously, Warda worked in public markets at CPP Investments where she ran a $500M public markets portfolio in the thematic investing team. She also worked at Point72 Asset Management, Bain & Company and Deutsche Bank. Warda has experience working in the United States, Canada, United Kingdom, Singapore, Hong Kong and Germany. Warda holds an MSc in Financial Economics from the University of Oxford, a BESc in Mechanical Engineering from the University of Western University and an HBA in Business Administration the Richard Ivey School of Business.
Second, Pedro's appointment as Partner in charge of investor relations underlines AVP's objective of managing more capital for top tier institutional investors. Pedro brings extensive experience in fundraising of technology funds, from his tenure at Target Global, where he played a key role in fundraising multiple tech funds and fostering investor relationships. He has also held senior positions at MVision and Hamilton Lane. Having started his career in the venture capital arm of FINEP, the Brazilian innovation agency, Pedro holds an MBA and a BSc in Industrial Engineering from Pontifícia Universidade Católica do Rio de Janeiro.
“On behalf of the AVP team, I am delighted to extend a warm welcome to Warda and Pedro as our newest Partners. I am also very proud that AVP can attract such talents, and in the case of Warda, convince top tier investor in the North American market to come to Paris. Warda will play a key role in developing our new Late Stage Fund strategy, focusing on Europe. With this new Late Stage fund, we now have the capability to support entrepreneurs throughout their journey, from the early stages to IPO, as well as post-IPO, which sets us apart in the market. Warda brings extensive knowledge and a proven track record in investing in Late Stage companies in the US and in Europe. In the context of our platform expansion and ongoing fundraising efforts across various strategies, we are very happy to benefit from Pedro’s substantial fundraising experience of technology focused fund. His background at Target Global will undoubtedly add value to the entire AVP platform. At AVP, nothing is more important than the quality, the diversity and the complementarity of the team. Since 8 years, we have welcomed 9 Partners and are now ready to further expand the team with these two talents. No doubt that they will play a key role in the next chapter of our journey," commented François Robinet, Managing Partner at AVP.
“I am thrilled to become a part of the outstanding team of investors at AVP. Since I was introduced to the firm, I recognized this platform had the vision, skills, and leadership to amplify the global landscape of technology investing with a diverse partnership that leverages expertise across the financing spectrum. AVP's Late Stage strategy in Europe addresses several challenges in the European ecosystem, including the shortage of local funding for exceptional European technology leaders to expand globally. At AVP, we look forward to bringing our collective knowledge to support such leaders at various stages in both the private and public markets,” commentedWarda Shaheen, General Partner at AVP.
“I am excited to join an incredibly talented team of investor at AVP. I have been fortunate to follow the development of the platform over the years and, now as part of the team, look forward to develop their robust capital base to attract additional top tier institutional investors globally,” commented Pedro Barros, Partner at AVP.
About AVP (AXA Venture Partners)
AVP (AXA Venture Partners) is a global venture capital firm specializing in high-growth, technology- enabled companies, managing more than $2 billion in assets across four investment strategies: Venture, Growth, Late Stage, and Fund of Funds. Since its establishment in 2016, AVP has invested in more than 60 technology companies in Venture and Growth stages in the US and Europe.
With offices in New York, London, and Paris, AVP supports companies in expanding internationally and provides portfolio companies with tailored business development opportunities to further accelerate their growth. AVP operates under AXA IM- Alts, the alternative investment business unit of AXA IM.
For more information, visit axavp.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502656787/en/
Contact information
AVP – Sébastien Loubry : sebastien@axavp.com / + 33 6 15 31 61 68
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press Release
Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of the EIOS:VSE stock reflects this strength: Price per Share (PPS): +132% in the first half (H1) of 2025, stabilizing at a +116% YTD increase. Daily Trading Volume: peaks of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press Release
500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to strengthen Morocco’s innovation and digital competitiveness by accelerating high-potential founders and providing the training and financing pa
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press Release
Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218764112/en/ Image courtesy of Neural Concept (L-R clockwise from top) Jonathan Donier, CSO & Co-founder; Thomas von Tschammer, Managing Director US & Co-founder; Théophile Allard, CTO & Co-founder; Pierre Baqué CEO & Co-founder; Philippe Cuendet, COO Neural Concept is redefining engineering workflows with CAD-native enterprise AI that understands geometry, constraints and design intent. By helping its customers build and deploy physics-aware design copilots, the platform enables teams to explore millions of design options earlier and avoid costly la
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press Release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special? MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
